NORML Demands Cannabis Consumers Get a Seat at the DEA Hearing

Every fight over cannabis policy has been waged between two camps — government agencies on one side, the industry and advocates on the other. One group has been almost entirely absent from the table: the tens of millions of Americans who actually use cannabis. As the DEA prepares for its pivotal June 29 rescheduling hearing, NORML is trying to change that, filing a formal Notice of Intention to Participate and making a pointed argument — that cannabis consumers must be represented in the decisions that govern their lives.

It's a small procedural filing with a big idea behind it.

The missing voice in cannabis policy

Think about how cannabis policy has historically been made. Regulators write the rules. Law enforcement enforces them. Industry lobbies over them. Researchers study around them. But the consumer — the person who buys the product, uses it responsibly, and bears the consequences of prohibition — has rarely had a formal seat in the room. For decades, policy about cannabis users was made almost entirely without them.

NORML's filing challenges that directly. By seeking to participate in the DEA's administrative hearing on moving botanical cannabis to Schedule III, the organization is asserting that consumers have a direct, legitimate stake in the outcome and deserve representation alongside the government and the industry. It's reframing rescheduling not just as a regulatory or business question, but as a consumer-rights one.

For fifty years, cannabis policy was made about consumers without consumers. NORML is arguing that era should end — starting at the most important federal hearing in a generation.

Why it resonates now

The timing gives the argument weight. The June 29 hearing is the most consequential cannabis proceeding in decades — the process that could move marijuana broadly from Schedule I to Schedule III, with sweeping implications for taxes, research, and the legal posture of the whole industry. If consumers are ever going to have a voice, the argument goes, it should be at a moment this pivotal.

There's also a credibility logic to it. Rescheduling decisions hinge partly on questions about cannabis's effects, its accepted uses, and its abuse potential — questions on which actual consumers have relevant, lived perspective. Hearing from the people who use the plant, NORML contends, produces better-informed policy than hearing only from regulators and businesses with their own interests.

The bigger shift it represents

Step back and this filing is part of a broader maturation in how cannabis is treated. As the plant moves from criminalized substance toward regulated product, the conversation is slowly expanding to include the people who consume it — not as suspects, but as stakeholders. That's a meaningful shift in posture, and one that mirrors how other consumer products are regulated, where user interests are a recognized part of the policy calculus.

Whether the DEA grants NORML a meaningful role, and whether consumer perspectives actually shape the outcome, remains to be seen — administrative hearings are technical, and participation doesn't guarantee influence. The opposition, including prohibitionist groups, will be making their own case. But the act of demanding a seat matters, because it plants a marker: consumers are a constituency, and their voice belongs in the room.

What it means for New Yorkers

For everyday consumers in New York and beyond, the immediate effect is abstract — you won't notice a change at the dispensary because NORML filed a notice. But the principle is consequential. The rules that determine product access, research, and the broader legal environment are shaped in proceedings like this one, and who's represented in them eventually shapes the experience of every consumer. In the meantime, the everyday reality of the legal market continues, and you can keep up with it by comparing cannabis deals across licensed dispensaries on High Today.

What participation actually involves

It helps to be realistic about what "a seat at the hearing" means. This is an administrative law proceeding before a judge, not a town hall — it runs on legal filings, evidence, and procedure, and getting a notice of intent accepted is only the first step. Participation can mean submitting evidence, examining the record, and making formal arguments, but it doesn't guarantee that a consumer perspective carries the day against government agencies and well-resourced opposition. Influence in these proceedings is earned through rigor, not just presence.

Still, the precedent is what makes it significant. If consumer advocates establish that they belong in a proceeding this consequential, it creates a template for the future — a recognition that consumer interests are a legitimate party in cannabis policymaking, not an afterthought. That matters beyond June 29, because the rescheduling fight is only one of many decisions ahead, from research rules to product standards to the eventual questions of broader legalization. Each of those will be shaped by whoever is in the room. NORML staking a claim now is partly about this hearing and partly about every hearing after it. Establishing the principle that consumers are stakeholders — once — makes it far easier to assert the next time. That long game is arguably the more important reason the filing is worth paying attention to.

The bottom line

NORML's filing won't dominate headlines the way the rescheduling itself does, but it represents a quietly important idea: that the people who use cannabis deserve a voice in the policies that govern it. After half a century of being legislated about rather than consulted, consumers asking for a seat at the most important federal cannabis hearing in a generation is more than a procedural footnote. It's an argument about who counts in this debate — and a sign that, as cannabis normalizes, the answer is finally starting to include the consumer. Whether the DEA agrees is its own question, and the opposition will push back hard. But the filing has already done part of its work simply by being made: it puts the consumer's claim on the record, where the next round of advocates can build on it.